Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. Notably, many targeted therapies are intended for patients with activating EGFR mutations, which are more prevalent in China than in the western markets. DRG expects the Chinese NSCLC therapy market to experience robust growth throughout the 2018-2028 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated approvals of immune checkpoint inhibitors. EGFR and ALK inhibitor drug classes will also drive market growth following the incorporation of several therapies into China’s National Reimbursement Drug List, thereby securing access to patients in need. Notable novel therapies from different drug classes, including four inhibitors for patients harboring either EGFR or ALK mutations, are expected to gain approval within the forecast period, resulting in increased therapy options and potent market growth.
- How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time?
- What is the current state of the China NSCLC market? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What are the key market access considerations of the most promising pipeline products? What sales/uptake could they secure in NSCLC? What therapies of note are progressing in earlier phases?
- What are key drivers and constraints in the China NSCLC market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.